Taysha Gene Therapies Q3 2026 net loss widens 20% to $39.1 million
TSHA•Taysha Gene Therapies’ third-quarter 2026 net loss widened 20% year over year to $39.1 million. It reported $422.8 million in cash and expects funding to support planned operations into the second half of 2028.
1. Quarterly results
Taysha Gene Therapies’ third-quarter net loss widened 20% year over year to $39.1 million. General and administrative expenses rose 58% to $13.1 million, and research and development expenses increased 12% to $28.8 million.
2. Cash and program updates
Cash and cash equivalents totaled $422.8 million at September 30, which the company expects to fund planned operations into the second half of 2028. Its TSHA-102 commercial-scale manufacturing validation campaign met predefined product specifications and comparability criteria, supporting a potential BLA submission. Six-month interim data from the REVEAL pivotal trial and FDA feedback on the TSHA-102 BLA submission pathway are expected in the first half of 2027.
